Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 263 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Financial Navigation Can Reduce the Financial Toxicity of Cancer Care April 21, 2023 Blood Test Accurately Detects Early-Stage Pancreatic Cancer May 10, 2024 Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical... December 20, 2022 FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... February 25, 2026 Load more HOT NEWS In memory of Dame Deborah James “If there is an under-representation of ethnic minority communities, there will... Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... Soaring skin cancer cases hit a record high
